PUBLICATIONS

18. E. Bergaggio*, W.T. Tai*, A. Aroldi, E. Landoni, M. Nuesch, I. Mota, J. Metovic, L. Ma, D. Alvarado, R. B. Blasco, T. Li, D. Klein, D. J. Irvine, M. Papotti, B. Savoldo, G. Dotti, R. Chiarle. ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells. In preparation. (2022)

17. L. Ma, D Morgan, C Backlund, I Sulkaj, W Abraham, N Li, C. Love, D. J. Irvine. A synthetic vaccine bridges CAR T cells and endogenous T cells to target tumors with pre-existing antigenic heterogeneity. In preparation. (2022)

 

16. L. Ma, W Ian, N. K. Mehta, B. Cossette, I Sulkaj, S. Harrison, D. Wittrup, D. J. Irvine. De novo engineered mimotope as a customized vaccine to enhance CAR T cell therapy. In preparation. (2022)

15. E Dane, A Belessiotis-Richards, C Backlund, J Wang, K Hidaka, L Milling, S Bhagchandani, M Melo, NA Li, N Donahue, K Ni, L Ma, M Okaniwa, M Stevens, A Alexander-Katz, D. J. Irvine. Delivery of STING agonists using tumor-penetrating PEGylated lipid nanodiscs primes sustained anti-cancer immunity. Nat Materials, (2022)

14.  E. Alspach, R. D. Chow, S. Demehri, J. L. Guerriero, S. Gujar, F. J. Hartmann, B. A. Helmink, W. H. Hudson, W. J. Ho, L. Ma, B. B. Maier, V. I. Maltez, B. C. Miller, A. E. Moran, E. M. Parry, P. S. Pillai, S. Rafiq, M. Reina-Campos, P. C. Rosato, N.-P. Rudqvist, M. K. Ruhland, I. Sagiv-Barfi, A. D. Sahu, R. M. Samstein, C. M. Schürch, D. R. Sen, D. S. Thommen, Y. Wolf, R. Zappasodi, Supporting the next generation of scientists to lead cancer immunology research. Cancer Immunol Res 9, canimm.0519.2021 (2021).

13. L. Ma, T. Dichwalkar, J. Y. H. Chang, B. Cossette, D. Garafola, A. Q. Zhang, M. Fichter, C. Wang, S. Liang, M. Silva, S. Kumari, N. K. Mehta, W. Abraham, N. Thai, N. Li, K. D. Wittrup, D. J. Irvine, Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor, Science 365, 162–168 (2019).

Editorial highlight “A boost for CAR–T cells” Science, 2019

“Amph-Ligand Vaccine Enhances CAR-T Cell Activity against Solid Tumors” Cancer discovery, 2019

Comment “Boosting engineered T cells” Science, 2019

Featured “CAR T cells get a boost inside lymph nodes” ACIR, 2019

12. N. Momin, N. K. Mehta *, N. R. Bennett *, L. Ma *, J. R. Palmeri, M. M. Chinn, E. A. Lutz, B. Kang, D. J. Irvine, S. Spranger, K. D. Wittrup, Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy, Sci Transl Med 11, eaaw2614 (2019). [* Equal contribution]

11. Chensu Wang*, Murillo Silva*, Leyuan Ma*, Bioengineering Innovative Solutions for Cancer. Elsevier (2019) [* Equal contribution]

10. L. Ma*, M. L. Pak*, J. Ou, J. Yu, P. St Louis, Y. Shan, L. Hutchinson, S. Li, M. A. Brehm, L. J. Zhu, M. R. Green, Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells, Proc. Natl. Acad. Sci. U.S.A. 116, 10482–10487 (2019). [* Equal contribution]

9. L. Ma, J. I. Boucher, J. Paulsen, S. Matuszewski, C. A. Eide, J. Ou, G. Eickelberg, R. D. Press, L. J. Zhu, B. J. Druker, S. Branford, S. A. Wolfe, J. D. Jensen, C. A. Schiffer, M. R. Green, D. N. Bolon, CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy, Proc. Natl. Acad. Sci. U.S.A. 114, 11751–11756 (2017).

8. L. Ma, J. Roderick, M. A. Kelliher, M. R. Green, High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML, Methods Mol. Biol. 1465, 159–173 (2016).

 

7. L. Ma, Y. Shan, R. Bai, L. Xue, C. A. Eide, J. Ou, L. J. Zhu, L. Hutchinson, J. Cerny, H. J. Khoury, Z. Sheng, B. J. Druker, S. Li, M. R. Green, A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia, Sci Transl Med 6, 252ra121–252ra121 (2014).

6. T. R. Wagenaar *, L. Ma *, B. Roscoe, S. M. Park, D. N. Bolon, M. R. Green, Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain, Pigment Cell Melanoma Res 27, 124–133 (2014). [* Equal contribution]

5. Z.-F. Yang, H. Zhang, L. Ma, C. Peng, Y. Chen, J. Wang, M. R. Green, S. Li, A. G. Rosmarin, GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2, Proc. Natl. Acad. Sci. U.S.A. 110, 2312–2317 (2013).

4. Z. Sheng, L. Ma, J. E. Sun, L. J. Zhu, M. R. Green, BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription, Blood 118, 2840–2848 (2011).

 

3. C.-Q. He, L.-Y. Ma, D. Wang, G.-R. Li, N.-Z. Ding, Homologous recombination is apparent in infectious bursal disease virus, Virology 384, 51–58 (2009).

2. C.-Q. He, Z.-X. Xie, G.-Z. Han, J.-B. Dong, D. Wang, J.-B. Liu, L.-Y. Ma, X.-F. Tang, X.-P. Liu, Y.-S. Pang, G.-R. Li, Homologous recombination as an evolutionary force in the avian influenza A virus, Mol. Biol. Evol. 26, 177–187 (2009).

 

1. G.-Z. Han, C.-Q. He, N.-Z. Ding, L.-Y. Ma, Identification of a natural multi-recombinant of Newcastle disease virus, Virology 371, 54–60 (2008).